Cuprina announced that Dr. Ronald Sherman has agreed to join the Company as Medical and Scientific Director in September 2025. Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical Maggots. This agreement gives Cuprina the right to manufacture, sell, use and distribute these maggots and associated dressings for use in maggot debridement therapy in the United States.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CUPR: